Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem ...

Tell your doctor if you are breastfeeding. Use Diltiazem Hydrochloride ER (Oral) exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for ...

Refer label for a detailed indication. Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg have an estimated market size of US$ 28.2 million for twelve months ending ...

Alembic Pharmaceuticals said that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Diltiazem Hydrochloride ...

Tell your doctor if you are breastfeeding. Use Diltiazem Hydrochloride SR (Oral) exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for ...

for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg. According to company’s statement, the approved ANDA is therapeutically equivalent to the ...

Alembic Pharmaceuticals Limited received final approval from the USFDA for Diltiazem Hydrochloride Extended-Release Capsules USP. The approved strengths include 120 mg, 180 mg, and 240 mg.

Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg. According to the company’s statement, the approved ANDA is therapeutically equivalent to the reference listed ...